Scholar Rock Holding (SRRK) Enterprise Value (2018 - 2026)
Scholar Rock Holding (SRRK) posted quarterly Enterprise Value of -$479.9 million for Q1 2026, down 31.72% year-over-year from -$702.9 million in Q1 2025, and down 30.57% quarter-over-quarter from -$367.6 million in Q4 2025.
Analysis
Scholar Rock Holding (SRRK) Enterprise Value (2018 - 2026) Analysis & Trends
Scholar Rock Holding's Enterprise Value history runs 10 years deep, the most recent figure standing at -$479.9 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 31.72% year-over-year to -$479.9 million; the TTM figure through Mar 2026 stood at -$479.9 million (down 31.72% YoY), while the FY2025 annual figure was -$367.6 million, up 15.94% from the prior year.
- Enterprise Value for Q1 2026 stood at -$479.9 million, down from -$367.6 million in the prior quarter.
- The five-year high for Enterprise Value was -$139.1 million in Q3 2024, with the low at -$479.9 million in Q1 2026.
- The 5-year median for Enterprise Value is -$295.0 million (2025), against an average of -$302.6 million.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value soared 36.39% in 2024, then tumbled 165.8% in 2025.
- Scholar Rock Holding's Enterprise Value stood at -$315.4 million in 2022, then advanced by 11.23% to -$279.9 million in 2023, then sank by 56.21% to -$437.3 million in 2024, then grew by 15.94% to -$367.6 million in 2025, then tumbled by 30.57% to -$479.9 million in 2026.
- Business Quant data shows SRRK's Enterprise Value at -$479.9 million in Q1 2026, -$367.6 million in Q4 2025, and -$369.6 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.87 Bn | 131.01 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.57 Bn | 77.57 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.19 Bn | 53.05 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.38 Bn | 32.07 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - |
| 9 | Insmed | 27.41 Bn | 26.25 Bn | 358.27 Mn |
| 10 | Scholar Rock Holding | 7.26 Bn | 7.26 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 6.20 Bn |
| Mar 31, 2026 | 5.38 Bn |
| Dec 31, 2025 | 4.41 Bn |
| Sep 30, 2025 | 3.32 Bn |
| Jun 30, 2025 | 3.11 Bn |
| Mar 31, 2025 | 2.69 Bn |
| Dec 31, 2024 | 3.62 Bn |
| Sep 30, 2024 | 502.39 Mn |
| Jun 30, 2024 | 475.84 Mn |
| Mar 31, 2024 | 1.18 Bn |
| Dec 31, 2023 | 1.15 Bn |
| Sep 30, 2023 | 353.67 Mn |
| Jun 30, 2023 | 355.36 Mn |
| Mar 31, 2023 | 361.60 Mn |
| Dec 31, 2022 | 152.28 Mn |
| Sep 30, 2022 | 206.14 Mn |
| Jun 30, 2022 | -142.18 Mn |
| Mar 31, 2022 | 244.82 Mn |
| Dec 31, 2021 | 621.60 Mn |
| Sep 30, 2021 | 896.04 Mn |